# Ablative Chemoembolization for Unresectable and Large Hepatocellular Carcinoma

> **NCT03662841** · NA · TERMINATED · sponsor: **Chinese University of Hong Kong** · enrollment: 11 (actual)

## Conditions studied

- Carcinoma, Hepatocellular

## Interventions

- **PROCEDURE:** Ablative chemoembolization (ACE)

## Key facts

- **NCT ID:** NCT03662841
- **Lead sponsor:** Chinese University of Hong Kong
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-07-13
- **Primary completion:** 2023-04-17
- **Final completion:** 2023-04-28
- **Target enrollment:** 11 (ACTUAL)
- **Why stopped:** poor patient accrual
- **Last updated:** 2023-05-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03662841

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03662841, "Ablative Chemoembolization for Unresectable and Large Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03662841. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*